August 10, 2022
RegMed Investors’ (RMi) closing bell: sector surges as algos didn’t want to miss out on inflation number’s slight tick-up
August 9, 2022
RegMed Investors’ (RMi) closing bell: something had to give, just too many earnings’ losses and missed revenue estimates
August 8, 2022
RegMed Investors’ (RMi) closing bell: sector rebounds from gutter to sidewalk action with lack luster earnings’ results
August 5, 2022
RegMed Investors’ (RMi) closing bell: follow the bouncing share pricing as acquisition re-heats sector
August 4, 2022
RegMed Investors’ (RMi) closing bell: gravity was not a downward force as anticipated
August 3, 2022
RegMed Investors’ (RMi) closing bell: the sector parties to the upside, the question is what happens when the music ends
August 2, 2022
RegMed Investors’ (RMi) closing bell: indexes are mixed as cell and therapy sector responds to being oversold with electronic trading
August 1, 2022
RegMed Investors’ (RMi) closing bell: an end of month tumble on Friday, a stumble on Monday, the first session of August
July 29, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector tumbles
July 28, 2022
RegMed Investors’ (RMi) closing bell: a focus on long-term investments will ruin short and near-term portfolio performance
July 27, 2022
RegMed Investors’ (RMi) closing bell: a share pricing roller coaster session
July 26, 2022
RegMed Investors’ (RMi) closing bell: reversing the curse of the oversold at the mid-day untill struck-down
July 22, 2022
RegMed Investors’ (RMi) closing bell: exiting the fire engulfed barn in a negative sector sell-off
July 21, 2022
RegMed Investors’ (RMi) closing bell: when investors stare into the downside, it’s not that deep
July 20, 2022
RegMed Investors’ (RMi) closing bell: upside strength sustains
July 19, 2022
RegMed Investors’ (RMi) closing bell: a relief rally, riding the high upside and rebound
July 18, 2022
RegMed Investors’ (RMi) closing bell: staring into the abyss as cell and gene therapy sector dives again
July 15, 2022
RegMed Investors’ (RMi) closing bell: ending the week with a sigh, it’s over as the sector closed positive
July 14, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector slumps as markets dump
July 12, 2022
RegMed Investors’ (RMi) closing bell: a bounce after a trounce
July 11, 2022
RegMed Investors’ (RMi) closing bell: this week’s expectation and economics
July 8, 2022
RegMed Investors’ (RMi) closing bell: sector moves up, neutral, down and back to the upside
July 7, 2022
RegMed Investors’ (RMi) closing bell: sector bounces back with some gene editors leading the charge
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.